RNA Avidity Biosciences, Inc.: Operating Margin

Avidity Biosciences, Inc. - graphic logo of issuer RNA

Avidity Biosciences (RNA) develops targeted RNA therapies, ensuring long-term demand for drugs treating muscle pathologies. However, a lack of revenue and high R&D expenses leave the company dependent on clinical trials. The innovative potential of AOC technologies is confirmed by the operating margin time series, where the value remains at -194.80, signaling the current state of the business model.

aviditybiosciences.com (RNA): Return on Sales by Operating Profit from 07/04/2022 to 11/19/2026

Metric breakdowns and analytics for aviditybiosciences.com (RNA)

- share price and consensus valuation forecast:
Initial company analysis:RNA, Avidity
Finished products of Avidity Biosciences

For Avidity Biosciences (RNA), the level of operating efficiency reflects the ability to generate profit amid geopolitical risks and the complexities of registering RNA-based drugs in foreign markets. This indicator is calculated as the ratio of operating profit to revenue, measuring the share of income after deducting all production costs but before taxes and interest, which allows for an objective assessment of the company's fundamental capital stability.

Competitor analysis for Avidity Biosciences

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|crisprtx.com - Operating Sales Margin|Operating Profit Rate WGS|RARE - Operating Profitability|Beam Tx (BEAM) - Operating Sales Margin|SRPT (Sarepta Therapeutics Inc) - Operating Sales Margin|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability